VIMIAN Vimian Group AB (publ)

4.331USD44.00 SEK · STO+1.15%Mkt Cap: 2.29B USDP/E: 57.89

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, pres…

Institutional holders10 on file

Key Statistics

Company
Market Cap2.29B USD
Enterprise Value25.50M USD
Revenue (TTM)512.10M USD
Gross Profit321.14M USD
Net Income (TTM)34.33M USD
Revenue/Share0.97 USD
Last Price4.331 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.0K
CountrySE
SectorHealthcare
IndustryDiagnostics & Research
ISINSE0015961982
Valuation
P/E (Trailing)57.89
P/E (Forward)33.08
PEG—
EV/EBITDA2.18
EV/Revenue0.05
P/S49.77
P/B31.38
EPS (TTM)0.83 USD
EPS (Forward)1.46 USD
52W Range
2.38099% of range4.351
52W High4.351 USD
52W Low2.380 USD
Profitability
Gross Margin68.89%
Oper. Margin18.03%
EBITDA Margin25.44%
Profit Margin7.36%
ROE4.48%
ROA2.82%
ROIC5.35%
ROCE6.76%
Growth
Revenue Growth15.30%
Earnings Growth67.20%
Cash Flow & Leverage
Operating CF115.93M USD
CapEx (TTM)16.56M USD
FCF Margin6.21%
FCF Yield1.39%
Net Debt246.34M USD
Net Debt/EBITDA1.89
Net Debt/FCF7.74
Balance Sheet
Debt/Equity0.34
Current Ratio2.73
Quick Ratio1.49
Book Value/Sh1.54 USD
Cash/Share114.34 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.164 USD
Upside (mean)-3.9%
Target Range3.507 USD – 4.521 USD
3.507-3.9% to mean4.521
# Analysts6
Ownership
Shares Out.527.14M
Float188.98K
Insiders5.44%
Institutions85.72%
Technical
SMA 503.753 (+15.4%)
SMA 2003.168 (+36.7%)
Beta0.99
S&P 52W Chg12.00%
Avg Vol (30d)310.56K
Avg Vol (10d)341.33K
Technical Indicators
RSI (14)77.9
MACD1.3815
MACD Signal1.3795
MACD Hist.+0.0021
BB Upper4.311 USD
BB Middle4.108 USD
BB Lower3.905 USD
BB Width9.88%
ATR (14)0.0903 USD
Vol Ratio (20d)1.01x

About Vimian Group (STO: VIMIAN)

›

Vimian Group (STO: VIMIAN) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 1,025 employees.

The shares were at 44.00 SEK on 19 November 2026, up 43.0% over 52 weeks. Its 52-week range is 24.18 SEK to 44.20 SEK, and it trades at the top of that range.

At a market capitalisation of 23.24B SEK, it trades at 57.9 times trailing earnings and 33.1 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a premium of 62% for VIMIAN.

Vimian Group reports return on equity of 4.5%, an operating margin of 18.0% and revenue up 15.3% year over year.

Its debt exceeds its cash by 224.60M EUR, a debt-to-equity ratio of 0.34. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 42.30 SEK is 3.9% below the current price. The next earnings report is expected on 11 February 2027.